hemophiliacs and healthy adults
Conditions
Interventions
A single blood collection
Sponsors
Jichi Medical University
Ogikubo Hospital Tokyo Medical University Hospital The University of Tokyo Hospital Research Hospital The Institute of Medical Science The University of Tokyo National Center for Global Health and Medicine St. Marianna University School of Medicine Nagoya University Hospital Mie University Hospital Nara Medical University Hospital The Hospital of Hyogo College of Medicine Hiroshima University Hospital Ehime University Hospital Munakata Suikokai General Hospital Shizuoka Children'
s Hospital Mitsubishi Tanabe Pharma Corporation
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Male hemophilia over 10 years old 2) Healthy adults at 20 to 69 years old
Exclusion criteria
Exclusion criteria: 1) The person who cannot obtain informed consent 2) Those who are treated with antibody drugs 3) Those who are treated by systemic administration of immunosuppressants (oral and injection) 4) Patients with the possibility of immunological abnormalities such as severe inflammatory diseases 5)The person judged to be ineligible by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The titer and prevalence of anti-AAV neutralizing antibody against several AAV serotypes | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Establishment of method to measure anti-AAV neutralizing antibody 2) Association of the prevalence of anti-AAV neutralizing antibody with age, gender, facility, and type of blood coagulation factor used for the therapy | — |
Countries
Japan
Contacts
Public ContactTsukasa Ohmori
Jichi Medical University Department of Biochemistry
Outcome results
None listed